M34.2
Systemic sclerosis induced by drug and chemical
Clinical Classification Guidelines
Use Additional Code
- code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
Code First
- poisoning due to drug or toxin, if applicable (T36-T65 with fifth or sixth character 1-4)
Medical Intelligence & Overview
Systemic sclerosis induced by drugs and chemicals is a rare condition where exposure to certain medications or chemicals triggers widespread hardening and tightening of the skin and connective tissues. This form of systemic sclerosis differs from primary systemic sclerosis, which occurs without known external triggers. The condition can affect various organs and tissues, leading to a range of health issues. Recognizing the underlying cause is crucial for appropriate management and treatment.
Causes & Symptoms
Clinical Causes: Exposure to certain medications such as chemotherapy agents, appetite suppressants, or certain antidepressants. Prolonged or high-level contact with industrial chemicals like silica, solvents, or vinyl chloride. Inadvertent or occupational exposure to toxic substances that might stimulate immune responses leading to tissue fibrosis. Genetic factors that might predispose some individuals to develop drug or chemical-induced sclerosis.
Key Symptoms: Thickening and hardening of the skin, often starting in the fingers and hands. Skin discoloration, appearing as patches of tight, shiny, or hardened skin. Swelling or puffiness near the affected areas. Joint stiffness and pain due to skin tightening around joints. Difficulties in movement caused by skin restrictions. Potential involvement of internal organs such as the lungs, heart, kidneys, or gastrointestinal tract, leading to symptoms like shortness of breath, chest discomfort, or digestive issues. Signs of systemic inflammation including fatigue, fever, and weight loss in more advanced cases.
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical examination, patient history, and laboratory tests. Key steps include: - Reviewing exposure history to potential causative drugs or chemicals. - Physical examination focusing on skin changes. - Laboratory tests such as autoantibody panels, including antinuclear antibodies (ANA), to assess immune activity. - Imaging studies like high-resolution CT scans for lung involvement. - Skin biopsies to confirm fibrosis and rule out other skin conditions. - Organ function tests for heart, lung, and kidney health to evaluate systemic impact.
Treatment Protocols: Managing drug or chemical-induced systemic sclerosis focuses on removing the offending agent when possible and addressing symptoms. Typical strategies include: - Discontinuation of the suspected causative medication or chemical exposure. - Use of immunosuppressive drugs like methotrexate or corticosteroids to reduce immune activity. - Symptomatic therapies for skin tightening, such as physical therapy or moisturizers. - Medications to improve blood flow and prevent vascular complications, including vasodilators. - Regular monitoring of internal organ function. - Supportive care, including managing joint pain and preventing complications like ulcers or infections. - In some cases, clinical trials or experimental therapies may be considered.
Clinical Advice & FAQs
Billing Guidance
Is M34.2 a billable ICD-10 code?
Yes, M34.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report M34.2?
Clinical documentation must specify the nature of Systemic sclerosis induced by drug and chemical and any associated comorbidities for accurate reporting.
Cite this Clinical Reference